On Jan. 16, the U.S. Securities and Exchange Commission announced settled charges against two former executives of Spero Therapeutics LLC, a public biopharmaceutical company, for misleading investors about the regulatory approval prospects of the company’s drug candidate.
Source: 3 Cases Highlight SEC Distinction Between Exec, Co. Liability